Outlook Therapeutics Incs. (OTLK) PT Raised to $6 at H.C. Wainwright
- Indexes close up more than 1% as investors assess Fed news
- China Tells Local Authorities to Prepare For a 'Possible Storm' and Prevent Unrest as Evergrande Crisis Unravels - WSJ
- Salesforce (CRM) Raises FY22 Revenue Guidance; Initiates FY23 Revenue
- Oil prices rise, hit 2-month highs on supply worries
- IDFA Seen as a 'Real Headwind' for Facebook (FB) but Analysts Remain Positive
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
H.C. Wainwright analyst Douglas Tsao raised the price target on Outlook Therapeutics Incs. (NASDAQ: OTLK) to $6.00 (from $5.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- China Finance Online (JRJC) halted on volatility after spiking 23.6% higher
- Morgan Stanley Upgrades Autoliv, Inc. (ALV) to Equalweight
- Lightspeed POS Inc. (LSPD) Gains on Toast IPO, Valuation
Create E-mail Alert Related CategoriesAnalyst PT Change, Momentum Movers, Trader Talk
Related EntitiesH.C. Wainwright
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!